Navigation Links
Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
Date:11/28/2007

Charles Bridges, MD, ScD, Associate Professor of Surgery at the University of Pennsylvania Medical Center and Chief of Cardiothoracic Surgery, Pennsylvania Hospital, has been awarded a $3 million grant from the National Heart, Lung and Blood Institute for his work in molecular cardiac surgery: a unique approach to gene therapy for heart failure.

The four-year grant will enable Dr. Bridges to expand upon his current research in large-animal molecular cardiac surgery (a term coined by Dr. Bridges). This methodology could provide alternatives both to heart transplantation and to the use of permanent mechanical-assist devices in some humans with end-stage heart failure. Molecular cardiac surgery, if successful, will be more powerful therapeutically and avoid the problems of rejection, infection, increased stroke risk and device failure often associated with these existing technologies.

Genes, which are carried on chromosomes, are the basic units of heredity. They produce proteins that directly or indirectly carry out all life functions. When genes are absent or defective, proteins are unable to carry out their normal functions, resulting in genetic disorders. In gene therapy, a functioning gene replaces an absent or faulty gene, so that the body can make the correct protein and consequently eliminate the root cause of a disease.

Using molecular cardiac surgery, Dr. Bridges group was the first in the world to convincingly demonstrate that marker genes could be efficiently inserted into the majority of heart muscle cells in large animals like dogs and sheep. What makes this approach so unique is that Dr. Bridges group uses a novel, patent-pending cardiac surgical procedure and specially designed hardware as a platform for the most efficient delivery of genes to heart muscle cells ever achieved in large animals. Prior to Dr. Bridges work, research in other laboratories had not proved successful in achieving global, heart-specific gene expression in animals other than rodents and mice.

The molecular cardiac surgical approach has an added advantage since genes are expressed only in the heart, enhancing the safety of this approach over all other available gene delivery methods. The preliminary success of molecular cardiac surgery opens the door to developing new treatments for a variety of heart muscle diseases causing heart failure.

A carrier called a vector is used to deliver the specially designed beneficial genes (transgenes). The most common vector is a virus that has been genetically altered. Viruses have evolved ways of delivering their genes to human cells in a pathogenic manner. Researchers have taken advantage of this capability by removing disease-causing genes from the virus and inserting therapeutic genes. The vector then discharges the therapeutic genes into the target cell. The new grant will enable Dr. Bridges to move beyond his work with marker genes and begin testing his findings using therapeutic genes in sheep with heart failure.

Dr. Bridges closely collaborates with Hansell Stedman, M.D., Associate Professor of Surgery at the University of Pennsylvania. Dr. Bridges and Dr. Stedman jointly have several U.S. and international patents for the efficient use of vectors in gene delivery to cardiac and skeletal muscle. Prior to their work, delivery techniques in common use typically resulted in one-to-two percent expression of therapeutic genes in the target cells. Dr. Bridges and Dr. Stedman generate successful delivery rates approaching 100 percent in both skeletal and cardiac muscle. In addition, their delivery methods enable safe removal of the delivery device once the therapeutic genes are delivered. This substantially reduces the risk of harm to other organs in the body.

"This grant will enable us to build on the advances my colleagues and I have been fortunate to achieve," says Dr. Bridges. "Molecular cardiac surgery offers genuine promise for eventually prolonging and enhancing the quality of life for many patients with heart disesase."

Dr. Bridges new study under the National Heart, Lung and Blood Institute grant will focus on one of the most promising transgene candidates with potential for healing the heart. Specifically, up to 100 trillion genes will be delivered to each heart, which is expected to arrest the progression of heart failure and possibly lead to recovery of heart function within several weeks.


'/>"/>

Contact: Lee-Ann Landis
landisl@uphs.upenn.edu
215-829-8043
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
2. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
3. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
4. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
5. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
6. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
7. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
8. Cardiologists and heart surgeons meet for Controversies and Advances conference
9. Rutgers Genetics receives $7.8 million for autism research
10. Herr receives Heinz Award for Technology, the Economy and Employment
11. UCI receives $5M from Edwards Lifesciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... , May 26, 2016 Despite ... see value in this space. Today,s pre-market research on ActiveWallSt.com ... Radius Health Inc. (NASDAQ: RDUS ), Cerus Corp. ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... technical briefings at: http://www.activewallst.com/ ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a Thai delegation at BIO 2016 in San Francisco. Located at booth number ... be available to answer questions and discuss the Thai biotechnology and life sciences ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... Last ... planning for corporate executives and entrepreneurs, held The Future of San Diego Life Science ... the San Diego life science community attended the event with speakers Dr. Rich Heyman, ...
Breaking Biology Technology: